Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CETAPRED vs ANOQUAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses.
Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.
Allergic and inflammatory disorders,Dermatologic diseases,Endocrine disorders,Ophthalmic conditions,Respiratory diseases,Rheumatic disorders
Hypertension
Ophthalmic suspension: Instill 1-2 drops into the conjunctival sac every 2-4 hours during the day; may increase to every 1-2 hours for severe inflammation. Periocular injection: 0.5-1 m L (20 mg/m L) as a subconjunctival or retrobulbar injection.
100 mg orally twice daily
Approximately 2-3 hours for prednisolone; clinical effects persist longer due to receptor-mediated actions.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic, primarily via CYP3A4.
Hepatic metabolism via oxidation and conjugation; metabolites excreted renally.
Renal (approximately 75% as metabolites, less than 10% unchanged) and fecal (<15%).
Renal excretion accounts for approximately 70% of the dose (50% as unchanged drug, 20% as inactive metabolites); biliary/fecal excretion accounts for 30%.
Prednisolone: 90-95% bound primarily to corticosteroid-binding globulin (CBG) and albumin.
Approximately 90% bound to albumin.
0.6-1.0 L/kg for prednisolone; reflects moderate tissue distribution.
0.8-1.2 L/kg, indicating extensive distribution into total body water.
Oral: approximately 70-90%; ophthalmic: systemic absorption minimal but variable.
Oral: 60-70% due to first-pass metabolism.
No dose adjustment required for renal impairment. Prednisolone acetate is primarily cleared via hepatic metabolism; renal excretion of metabolites is minor.
GFR 30-50 m L/min: 100 mg once daily; GFR <30 m L/min: 50 mg once daily; not recommended for GFR <15 m L/min
For Child-Pugh class A (mild): No adjustment. Child-Pugh class B (moderate): Reduce dose by 50% or administer every other day. Child-Pugh class C (severe): Avoid use or use with extreme caution; reduce dose by 75%. Prednisolone undergoes hepatic metabolism, and accumulation may occur in severe impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: not recommended
Instill 1 drop into the conjunctival sac every 2-4 hours; may increase to every 1-2 hours if needed. For subconjunctival injection: 0.1-0.5 m L (20 mg/m L) based on age and weight. Use lowest effective dose to minimize systemic effects.
Not approved for pediatric use; no established dosing
Use the lowest effective dose and shortest duration. Monitor intraocular pressure closely due to increased risk of corticosteroid-induced glaucoma. Consider concurrent use of artificial tears. No specific dose adjustment but caution with systemic absorption.
No specific adjustment; monitor renal function and consider reduced initial dose (50 mg twice daily) in patients >65 years with renal impairment
None.
No FDA black box warning.
Immunosuppression and increased infection risk,Adrenal suppression with prolonged use,Osteoporosis with long-term use,Cushing's syndrome with high doses,Growth suppression in children,Ocular effects (cataracts, glaucoma),Psychiatric disturbances,Gastrointestinal perforation risk,Fluid and electrolyte disturbances
Rebound hypertension upon abrupt discontinuation; sedation and drowsiness; potential for orthostatic hypotension; caution in patients with severe coronary insufficiency or cerebrovascular disease.
Systemic fungal infections,Hypersensitivity to any component,Administration of live or live attenuated vaccines in immunosuppressive doses
Known hypersensitivity to guanabenz; patients with severe hepatic or renal impairment.
No known food interactions with ophthalmic use. Systemic absorption is minimal, but if accidentally ingested, avoid excessive sodium intake due to sulfacetamide sodium content.
Avoid grapefruit and grapefruit juice as they may increase quinine levels. Take with a full glass of water. May be taken with meals to reduce nausea.
CETAPRED (betamethasone/prednisolone) is a corticosteroid. First trimester: increased risk of oral clefts (odds ratio ~3.4). Second/third trimester: associated with fetal adrenal suppression, intrauterine growth restriction, and preterm delivery with prolonged use.
Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and third trimester exposure is associated with fetal nephrotoxicity, oligohydramnios, and premature closure of the ductus arteriosus.
Prednisolone enters breast milk with a milk-to-plasma ratio of 0.1-0.3. Doses up to 40 mg/day considered safe; higher doses may cause infant adrenal suppression. Monitor infant for growth and adrenal function.
Excreted in human milk. M/P ratio not determined. Avoid breastfeeding due to potential for serious adverse reactions in the nursing infant, including renal impairment and electrolyte disturbances.
Prednisolone clearance increases up to 1.5-fold in late pregnancy; consider 20% dose increase for anti-inflammatory effect. Betamethasone (for fetal lung maturity) uses standard dose (12 mg IM x2).
Anoquan is contraindicated in pregnancy; no dose adjustments are recommended because use during pregnancy is not advised.
Cetapred (prednisolone acetate 0.25% and sulfacetamide sodium 10%) ophthalmic suspension is used for corticosteroid-responsive ocular conditions with concurrent bacterial infection or risk of infection. Shake vigorously before each use. Monitor intraocular pressure (IOP) with use >10 days. Prolonged use may lead to cataract formation, secondary infection, or corneal perforation in diseases causing corneal thinning. Do not use for viral, fungal, or mycobacterial infections. Avoid contamination of dropper tip.
ANOQUAN (quinine sulfate) is used for uncomplicated Plasmodium falciparum malaria. Monitor for cinchonism (tinnitus, headache, nausea). Avoid in G6PD deficiency due to hemolysis risk. Correct hypoglycemia frequently. Use with caution in atrial fibrillation due to QT prolongation.
Shake the bottle well before each use.,Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Temporary blurred vision may occur; do not drive or operate machinery until vision clears.,Report any eye pain, vision changes, or worsening redness to your doctor immediately.,Do not stop using this medication without consulting your doctor even if symptoms improve.,Keep out of reach of children. Store at room temperature away from light and moisture.
Take with food to reduce gastrointestinal upset.,Complete full course even if symptoms improve.,Report ringing in ears, confusion, or vision changes.,Avoid driving if dizziness or visual disturbances occur.,Inform doctor of any history of G6PD deficiency or cardiac arrhythmias.
No interactions on record
No interactions on record
Common clinical questions about CETAPRED vs ANOQUAN, answered by our medical review team.
CETAPRED is a Ophthalmic combination (antibiotic/corticosteroid) that works by Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses.. ANOQUAN is a Local Anesthetic that works by Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CETAPRED and ANOQUAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CETAPRED is: Ophthalmic suspension: Instill 1-2 drops into the conjunctival sac every 2-4 hours during the day; may increase to every 1-2 hours for severe inflammation. Periocular injection: 0.5-1 m L (20 mg/m L) as a subconjunctival or retrobulbar injection.. The standard adult dose of ANOQUAN is: 100 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CETAPRED and ANOQUAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CETAPRED is classified as Category C. CETAPRED (betamethasone/prednisolone) is a corticosteroid. First trimester: increased risk of oral clefts (odds ratio ~3.4). Second/third trimester: associated with fetal adrenal s. ANOQUAN is classified as Category C. Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.